The long-term goal of the Genomics of Acute Myeloid Leukemia Program Project Grant (GAML PPG) is to define all of the genetic events that contribute to the pathogenesis of AML, and to use this information to improve the risk assessment and treatment of patients with this disease. This goal will be addressed in a highly integrated and productive PPG structure that involves four projects and four cores. During the past 5 years, the members of this PPG developed the approaches (that are now widely used) to perform whole genome sequencing of AML genomes, and to validate all variants with custom capture arrays and deep digital sequencing. We have contributed 200 AML samples to The Cancer Genome Atlas for their AML project, which is led by two of our PPG members (Ley and Wilson). Although analysis of this enormous dataset is ongoing, these studies have led to the discovery of more than 200 recurrently mutated genes in AML, including DNMT3A, U2AF1, and IDH1, representing new classes of mutations that were not previously (

Public Health Relevance

Acute myeloid leukemia is a heterogeneous group of malignancies of blood forming cells that are associated with a high rate of relapse and death, even with state-of-the-art therapy. The genetic basis of the disease must be solved so that risk assessment can be improved, and novel therapeutic approaches can be developed. We are sequencing the genomes and transcriptomes of AML cases to define the genetic factors that contribute to drug resistance and early relapse, which may provide new approaches for therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (J1))
Program Officer
Li, Jerry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Al-Hussaini, Muneera; Rettig, Michael P; Ritchey, Julie K et al. (2016) Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood 127:122-31
Welch, John S; Petti, Allegra A; Miller, Christopher A et al. (2016) TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375:2023-2036
Wong, Terrence N; Miller, Christopher A; Klco, Jeffery M et al. (2016) Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 127:893-7
Griffith, Malachi; Griffith, Obi L; Krysiak, Kilannin et al. (2016) Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol 44:603-13
Cole, Christopher B; Verdoni, Angela M; Ketkar, Shamika et al. (2016) PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest 126:85-98
Churpek, Jane E; Pyrtel, Khateriaa; Kanchi, Krishna-Latha et al. (2015) Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126:2484-90
Wong, Terrence N; Ramsingh, Giridharan; Young, Andrew L et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552-5
Engle, E K; Fisher, D A C; Miller, C A et al. (2015) Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29:869-76
Griffith, Malachi; Miller, Christopher A; Griffith, Obi L et al. (2015) Optimizing cancer genome sequencing and analysis. Cell Syst 1:210-223
Lu, Charles; Xie, Mingchao; Wendl, Michael C et al. (2015) Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun 6:10086

Showing the most recent 10 out of 98 publications